ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

被引：0
|
作者：
Tina Kringelbach
Martin Højgaard
Kristoffer Rohrberg
Iben Spanggaard
Britt Elmedal Laursen
Morten Ladekarl
Charlotte Aaquist Haslund
Laurine Harsløf
Laila Belcaid
Julie Gehl
Lise Søndergaard
Rikke Løvendahl Eefsen
Karin Holmskov Hansen
Annette Raskov Kodahl
Lars Henrik Jensen
Marianne Ingerslev Holt
Trine Heide Oellegaard
Christina Westmose Yde
Lise Barlebo Ahlborn
Ulrik Lassen
机构：
[1] Rigshospitalet,Department of Oncology, Phase 1 Unit
[2] Aarhus University,Department of Molecular Medicine/Department of Oncology, Aarhus University Hospital, and Institute of Biomedicine, Pharmacology/Precision Medicine
[3] Aalborg University Hospital,Department of Oncology, Clinical Cancer Research Center
[4] Zealand University Hospital,Department of Clinical Oncology and Palliative Care
[5] University of Copenhagen,Department of Clinical Medicine, Faculty of Health and Medical Sciences
[6] Herlev Gentofte Hospital,Department of Oncology
[7] Odense University Hospital,Department of Oncology, Clinic of Precision Medicine
[8] University of Southern Denmark,Department of Clinical Research
[9] Vejle Hospital and University Hospital of Southern Denmark,Department of Oncology
[10] Vejle Hospital and University Hospital of Southern Denmark,Department of Clinical Genetics
[11] Aarhus University,Department of Oncology, Goedstrup Hospital, Goedstrup, and Department of Clinical Medicine
[12] Rigshospitalet,Center for Genomic Medicine
来源：
BMC Cancer | / 23卷
关键词：
Cancer genetics; Targeted therapies; Clinical trials; Cancer immunotherapy; Precision oncology; Tumor-agnostic therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
    Altan, Mehmet
    Wang, Yan
    Song, Juhee
    Welsh, James
    Tang, Chad
    Guha-Thakurta, Nandita
    Blumenschein, George R.
    Carter, Brett W.
    Wefel, Jeffrey S.
    Ghia, Amol J.
    Yeboa, Debra N.
    McAleer, Mary Frances
    Chung, Caroline
    Woodhouse, Kristina D.
    McGovern, Susan L.
    Wang, Chenyang
    Kim, Betty Y. S.
    Weinberg, Jeffrey S.
    Briere, Tina M.
    Elamin, Yasir Y.
    Lee, Xiuning
    Cascone, Tina
    Negrao, Marcelo, V
    Skoulidis, Ferdinandos
    Ferrarotto, Renata
    Heymach, John, V
    Li, Jing
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (07)
  • [42] Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
    Le Tourneau, Christophe
    Delord, Jean-Pierre
    Goncalves, Anthony
    Gavoille, Celine
    Dubot, Coraline
    Isambert, Nicolas
    Campone, Mario
    Tredan, Olivier
    Massiani, Marie-Ange
    Mauborgne, Cecile
    Armanet, Sebastien
    Servant, Nicolas
    Bieche, Ivan
    Bernard, Virginie
    Gentien, David
    Jezequel, Pascal
    Attignon, Valery
    Boyault, Sandrine
    Vincent-Salomon, Anne
    Servois, Vincent
    Sablin, Marie-Paule
    Kamal, Maud
    Paoletti, Xavier
    LANCET ONCOLOGY, 2015, 16 (13): : 1324 - 1334
  • [43] Tramadol hydrochloride/acetaminophen combination versus non-steroidal anti-inflammatory drug for the treatment of perioperative pain after total knee arthroplasty: A prospective, randomized, open-label clinical trial
    Mochizuki, Takeshi
    Yano, Koichiro
    Ikari, Katsunori
    Hiroshima, Ryo
    Takaoka, Hiromitsu
    Kawakami, Kosei
    Koenuma, Naoko
    Ishibashi, Mina
    Shirahata, Toshikatsu
    Momohara, Shigeki
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2016, 21 (05) : 625 - 629
  • [44] Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial
    Hyman, D. M.
    Piha-Paul, S. A.
    Rodon, J.
    Saura, C.
    Puzanov, I.
    Shapiro, G. I.
    Loi, S.
    Joensuu, H.
    Hanrahan, A. J.
    Modi, S.
    Lalani, A. S.
    Xu, F.
    Garza, S. J.
    Cutler, R. E.
    Bryce, R.
    Meric-Bernstam, F.
    Baselga, J.
    Solit, D. B.
    CANCER RESEARCH, 2016, 76
  • [45] Comparative clinical efficacy of acupuncture combined with manipulation and other non-pharmacological interventions in the treatment of lumbar disc herniation: a prospective, multi-arm, randomized, open-label, blinded endpoint trial
    Shi, Fudong
    Wen, Haibao
    Liu, Yuzhang
    Li, Zuoxu
    Jin, Jiao
    Liu, Ning
    Wang, Guojun
    Chen, Chun
    Feng, Yadi
    Lin, Hai
    Zhang, Shimin
    FRONTIERS IN MEDICINE, 2025, 11
  • [46] Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial
    Godeaux, Olivier
    Kovac, Martina
    Shu, Daniel
    Grupping, Katrijn
    Campora, Laura
    Douha, Martine
    Heineman, Thomas C.
    Lal, Himal
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (05) : 1051 - 1058
  • [47] Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial
    Turner, Nicholas A.
    Zaharoff, Smitha
    King, Heather
    Evans, Scott
    Hamasaki, Toshimitsu
    Lodise, Thomas
    Ghazaryan, Varduhi
    Beresnev, Tatiana
    Riccobene, Todd
    Patel, Rinal
    Doernberg, Sarah B.
    Rappo, Urania
    Fowler, Vance G., Jr.
    Holland, Thomas L.
    TRIALS, 2022, 23 (01)
  • [48] (Trial in Progress) A phase 2, open-label, randomized multicenter trial to evaluate neoadjuvant lasofoxifene in molecularly-selected HR+/HER2-Clinical Stage 2/3 breast cancer
    Chien, J.
    Esserman, L.
    Elias, A.
    Wei, M.
    Plourde, P.
    Portman, D.
    BREAST, 2023, 68 : S66 - S66
  • [49] Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial
    Nicholas A. Turner
    Smitha Zaharoff
    Heather King
    Scott Evans
    Toshimitsu Hamasaki
    Thomas Lodise
    Varduhi Ghazaryan
    Tatiana Beresnev
    Todd Riccobene
    Rinal Patel
    Sarah B. Doernberg
    Urania Rappo
    Vance G. Fowler
    Thomas L. Holland
    Trials, 23
  • [50] The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)
    Turner, Nicholas
    Bye, Hannah
    Kernaghan, Sarah
    Proszek, Paula
    Fribbens, Charlotte
    Moretti, Laura
    Morden, James
    Snowdon, Claire
    Macpherson, Iain
    Wardley, Andrew
    Roylance, Rebecca
    Baird, Richard
    Bliss, Judith
    Ring, Alistair
    CANCER RESEARCH, 2018, 78 (04)
12345